---
title: "Polar Asset Management Partners Inc. Makes New $39.05 Million Investment in Johnson & Johnson (NYSE:JNJ)"
description: "Polar Asset Management Partners Inc. has made a new investment of approximately $39.05 million in Johnson & Johnson (NYSE: JNJ) by acquiring 270,000 shares during the 4th quarter. This investment come"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/241836926.md"
published_at: "2025-05-26T10:56:33.000Z"
---

# Polar Asset Management Partners Inc. Makes New $39.05 Million Investment in Johnson & Johnson (NYSE:JNJ)

> Polar Asset Management Partners Inc. has made a new investment of approximately $39.05 million in Johnson & Johnson (NYSE: JNJ) by acquiring 270,000 shares during the 4th quarter. This investment comes as several other hedge funds also increased their stakes in the company. Johnson & Johnson's stock has received mixed ratings from analysts, with a consensus target price of $170.88. The company recently reported strong quarterly earnings, exceeding analysts' expectations, and announced a quarterly dividend of $1.30 per share.

Polar Asset Management Partners Inc. bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 270,000 shares of the company's stock, valued at approximately $39,047,000.

Get **Johnson & Johnson** alerts:

-   3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market

Several other hedge funds have also recently modified their holdings of JNJ. WealthTrak Capital Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $32,000. Conquis Financial LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $33,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $36,000. Institutional investors own 69.55% of the company's stock.

## Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. The trade was a 25.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

## Wall Street Analyst Weigh In

-   3 Industry Behemoths Are Rewarding Investors With Dividend Bumps

Several equities research analysts have recently issued reports on the stock. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Bank of America decreased their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Royal Bank of Canada restated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 16th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $170.88.

**Get Our Latest Analysis on Johnson & Johnson**

## Johnson & Johnson Stock Up 0.3%

-   3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

Shares of NYSE:JNJ opened at $153.12 on Friday. The firm has a fifty day moving average price of $155.24 and a two-hundred day moving average price of $153.69. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a market cap of $368.41 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

## Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's payout ratio is currently 57.84%.

## Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

## Further Reading

-   Five stocks we like better than Johnson & Johnson
-   What is the Australian Securities Exchange (ASX)
-   Trade Desk Silences Critics; Recovery Looks Poised to Continue
-   What is the S&P 500 and How It is Distinct from Other Indexes
-   Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock
-   What does consumer price index measure?
-   These ETFs Provide Easy Exposure to Growing International Markets

**Want to see what other hedge funds are holding JNJ?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [JNJ.US - Johnson & Johnson](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 强生｜10-K：2025 财年营收 942 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275658131.md) |
| 关键事实：强生在滑石粉案件中被判负有责任；已对贷款人提起 3,000 万美元的诉讼 | 宾夕法尼亚州的陪审团裁定强生公司对其滑石粉婴儿粉与癌症相关的责任，判给原告 25 万美元。该公司计划上诉，目前有超过 67,000 起类似的诉讼。Smith Law Firm 已对贷款方提起诉讼，涉及 3000 万美元的贷款，声称他们的目标 | [Link](https://longbridge.com/en/news/275986663.md) |
| 谷歌突然发布 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌发布了最新的大模型 Gemini 3.1 Pro，其推理性能较去年发布的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 评测中，Gemini 3.1 Pro 得分 77.1%，显示出强大的推理能力。新模型支持多源数据综合和复杂 | [Link](https://longbridge.com/en/news/276396515.md) |
| 沃尔玛四季度财报超预期但盈利指引不及预期，CEO 称 “美国低收入家庭只能勉强维持生计” | 沃尔玛 Q4 营收超预期，新财年盈利指引（每股 2.75-2.85 美元）远低于市场预期的 2.96 美元，显示通胀压力下消费者支出不确定性犹存，拖累股价下跌 1.38%。财报印证 K 型” 分化：高收入家庭驱动增长，低收入群体 “钱包吃紧 | [Link](https://longbridge.com/en/news/276398633.md) |
| 最高法裁决后特朗普动用替补选择：加征 10% 全球关税 | 美国总统特朗普在最高法院裁决后宣布将加征 10% 的全球关税，以补救被推翻的关税措施。根据《1974 年贸易法》第 122 条款，现有的关税将全面生效。最高法院裁定特朗普政府的部分关税措施缺乏法律授权。市场风险提示，投资需谨慎。 | [Link](https://longbridge.com/en/news/276477629.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
